Drug Shortage Report for SANDOZ TELMISARTAN HCT
Report ID | 179524 |
Drug Identification Number | 02393557 |
Brand name | SANDOZ TELMISARTAN HCT |
Common or Proper name | TELMISARTAN HCT 80/12.5MG |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE TELMISARTAN |
Strength(s) | 12.5MG 80MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30FCT |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Shortage of an inactive ingredient or component. |
Anticipated start date | |
Actual start date | 2022-12-21 |
Estimated end date | 2023-01-13 |
Actual end date | 2023-01-18 |
Shortage status | Resolved |
Updated date | 2023-01-19 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2023-01-19 | French | Compare |
v3 | 2023-01-19 | English | Compare |
v2 | 2022-12-28 | French | Compare |
v1 | 2022-12-28 | English | Compare |
Showing 1 to 4 of 4